November 7, 2023
Concluded a license agreement with AlliedCel Corporation.
JUNTEN BIO Co., Ltd has Concluded a license agreement with AlliedCel Corporation, a Joint Venture Between Sysmex and JCR Pharmaceuticals.
Sysmex Corporation News Release
https://www.sysmex.co.jp/en/news/2023/231107.html
JCR Pharmaceuticals News Release
November 1, 2023
Notice Regarding the Issue of Unsecured Straight Bonds
JUNTEN BIO Co., Ltd. announced on October 31, 2023 that it has issued corporate bond and share acquisition right to Mizuho venture debt fund. This topic is the first case with Mizuho venture debt fund.
July 6, 2022
The article introducing our company was published in the Nikkei (morning newspaper, July 6, 2022).
https://www.nikkei.com/
January 31, 2022
Juntendo Immune Tolerance Project website had been updated.
November 26, 2021
Juntendo Immune Tolerance Project website had been updated.
